<< Back
Vitae Pharmaceuticals is named one of the Best Places to Work in Pennsylvania

Fort Washington, PA, December 2, 2010 -- Vitae Pharmaceuticals announced today that the Company has been named one of the 100 Best Places to Work in PA for 2010. The awards program, created in 2000, is one of the first statewide programs of its kind in the country. The program is a public/private partnership between Team Pennsylvania Foundation, the Pennsylvania Department of Community and Economic Development and the Central Penn Business Journal.

Vitae President and CEO Jeffrey Hatfield commented, “We are a small company with big aspirations. Vitae is comprised of exceptional scientists working together to find novel solutions to some of the world’s most debilitating diseases - kidney disease, diabetes, Alzheimer’s and atherosclerosis. We know the challenges are daunting and the risks high, but our early successes energize and unite us, and the ultimate reward – the opportunity to make life better for millions of people around the globe – drives us forward with tremendous urgency and passion.”

The Best Places to Work survey and awards program was designed to identify, recognize and honor the best places to be employed in Pennsylvania, benefiting the state’s economy, its workforce and businesses. Companies from across the state entered the two-part assessment process, which included 1) evaluating each nominated company’s workplace policies, practices, philosophies, systems and demographics; and 2) an employee survey to measure the employee experience.

Vitae was recognized in an evening awards ceremony on Tuesday, November 30, 2010, at the Lancaster County Convention Center in Lancaster, PA. For more information on Best Places to Work in PA, visit www.bestplacestoworkinpa.com.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large markets, including chronic kidney disease, diabetes, Alzheimer’s disease and atherosclerosis. Vitae’s lead compound, VTP-27999, is a wholly owned, novel, potent and selective renin inhibitor offering the potential for superior renal protection in patients suffering from chronic kidney disease. The compound is advancing through Phase I clinical trials and results will be presented by early 2011.

Vitae is an expert in structure-based drug discovery and combines a proprietary technical platform with the experience and insight of world class scientists to advance best-in-class compounds for high value, hard-to-drug targets. Vitae’s proprietary, discovery platform has clear advantages in creating and analyzing novel drug candidates that meet pre-defined physicochemical characteristics. The accuracy and speed of this system has enabled Vitae to solve challenging targets in multiple therapeutic areas -- discovering and advancing attractive compounds in a rapid and highly capital efficient manner. Vitae Pharmaceuticals is financed by leading corporate and venture capital investors; its last venture round was in 2004. Vitae’s 45 scientists are located in Fort Washington, Pennsylvania. For additional information, please visit the company’s website, www.vitaepharma.com.


Burns McClellan on behalf of Vitae

Justin Jackson, Michelle Szwarcberg (media),




"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Vitae Pharmaceuticals Inc's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.